Targovax ASA announced the appointment of Dr. Lone Ottesen as Chief Development Officer (CDO). She will take a leading role in driving the clinical programs forward. Dr. Ottesen will serve as a member of Targovax's management team. Dr. Ottesen is a highly experienced drug developer with extensive experience across the global oncology and immune-oncology drug development spectrum with nearly 20 years in the pharmaceutical industry in both early- and late-phase development. Lone got her MD and PhD at Aarhus University in Denmark and has held roles of increasing seniority in GSK, Eisai and latest AstraZeneca where she was the Global Clinical Head for two assets in pivotal clinical development as well as leading the development of durvalumab in breast and gynecological cancers. Lone will be spearheading the clinical development program for the Targovax portfolio including the planned registration-directed trial in anti-PD1 refractory melanoma for the lead asset ONCOS-102. Dr. Ottesen commences as Chief Development Officer 1 July 2021.